Gina Mauro | Authors

Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior Therapy

May 21, 2022

Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.

Canakinumab Combination Doesn’t Lead to Survival Improvement But Could Benefit Subgroups With Advanced NSCLC

April 14, 2022

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

Intraperitoneal Carboplatin Plus Paclitaxel Improves PFS in Ovarian Cancer, Yet OS Results Remain Unchanged Vs IV Chemo

March 20, 2022

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.